Cagrilintide With Semaglutide: A Way to Prevent Diabesity?

CagriSema (cagrilintide plus semaglutide) led to weight loss 'of a magnitude not previously reported with pharmacotherapies in type 2 diabetes,' plus improved CGM measures, in a phase 2 trial.
Medscape Medical News

source https://www.medscape.com/viewarticle/993665?src=rss

Comments

Popular posts from this blog

A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?

New AAFP practice guideline sets blood pressure targets for adults with hypertension